Literature DB >> 21559633

Bacillus-calmette-guerin (bcg) organisms directly alter the growth of bladder-tumor cells.

A Jackson1, A Alexandroff, D Fleming, S Prescott, G Chisholm, K James.   

Abstract

Studies in recent years have shown various effects of bacillus Calmette Guerin organisms on the human immune system. In the present study, the direct effects of bacillus Calmette Guerin (BCG) (as used for the clinical management of superficial bladder cancer) on bladder tumour cells were investigated. Using a proliferation assay, changes in the growth rates of tumour cells were studied following direct exposure to BCG. The effects of variations in the BCG dose, and in the viability of BCG organisms were investigated and our initial observations concerning the antiproliferative effects of interferon-garnma were extended. The main finding of these studies is the direct immuno-modulatory effects of BCG organisms on the proliferative capacity of human tumour cells. Previously these alterations in the growth rate of bladder cancer cells, which are observed following patient therapy, were attributed to the production of various cytokines. However, after exposure to BCG the growth of tumour cell lines was suppressed in a dose and time dependent manner. Furthermore, both viable and nonviable bacilli can exert this action although heat killed BCG may be less effective in doing so. In concordance with our earlier study, interferon-gamma exerted marked antiproliferative effects against eight tumour cell lines. Furthermore, a 12 hour pulse of cytokine was sufficient to suppress the growth of tumour cells. This is an important finding as cytokine is not detected in patient's urine later than 12 hours after immunotherapy. No consistent pattern of growth altering effect was observed with any of the other cytokines tested (IL-1-alpha, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, GM-CSF). Our study suggests that BCG organisms per se may exert direct effects upon tumour cells in vivo and thus ease the load on the immune responses leading to the eventual eradication of tumour.

Entities:  

Year:  1994        PMID: 21559633     DOI: 10.3892/ijo.5.3.697

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Authors:  Romulus Breban; Aurelie Bisiaux; Claire Biot; Cyrill Rentsch; Philippe Bousso; Matthew L Albert
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology.

Authors:  Gopitkumar Shah; Guangjian Zhang; Fanghong Chen; YanLi Cao; Balaraman Kalyanaraman; William A See
Journal:  J Urol       Date:  2015-12-13       Impact factor: 7.450

3.  Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha.

Authors:  J L Haley; D G Young; A Alexandroff; K James; A M Jackson
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

Review 4.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

5.  Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro.

Authors:  K Pryor; P Stricker; P Russell; D Golovsky; R Penny
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

6.  Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure.

Authors:  Gopitkumar Shah; Guangjian Zhang; Fanghong Chen; YanLi Cao; Balaraman Kalyanaraman; William See
Journal:  J Urol       Date:  2013-09-11       Impact factor: 7.450

7.  Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

8.  The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis.

Authors:  Ziqi Ye; Jie Chen; Yun Hong; Wenxiu Xin; Si Yang; Yuefeng Rao
Journal:  Onco Targets Ther       Date:  2018-08-08       Impact factor: 4.147

Review 9.  BCG in Bladder Cancer Immunotherapy.

Authors:  Song Jiang; Gil Redelman-Sidi
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

10.  Renal Granulomatosis Post Intravesical Bacillus Calmette-Guerin Therapy for Non-muscle-invasive Bladder Cancer.

Authors:  Karen Tran-Harding; Rashmi T Nair; Halemane Ganesh
Journal:  J Clin Imaging Sci       Date:  2018-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.